ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients

NCT06195709 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Breast Carcinoma

Interventions

COMBINATION_PRODUCT: Endocrine therapy
COMBINATION_PRODUCT: Endocrine therapy combined with the local treatment of FES-negative lesions
COMBINATION_PRODUCT: Chemotherapy

Sponsor

Institut Curie

Collaborators

[object Object]